Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.68 |
| ▸ | PNMT | P11086 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805405 | 1.00 | CD44 (0.68) | CD44PNMTALDH1A1HPGDKDM4E | |
| SCHEMBL329571 | 0.81 | CD44 (1.00) | CD44PNMTMAOBPARP1PRCP | |
| SCHEMBL29771844 | 0.81 | CD44 (1.00) | CD44PNMTMAOBPARP1PRCP | |
| SCHEMBL3659651 | 0.81 | CD44 (0.72) | CD44PNMTMAOBPRCP | |
| SCHEMBL30156803 | 0.81 | CD44 (0.72) | CD44PNMTMAOBPRCP | |
| Tert-Butyl Formate SCHEMBL28294146 | 0.80 | CD44 (0.47) | CD44TDP1 | |
| Hydrochloric Acid SCHEMBL4516826 | 0.79 | CD44 (0.70) | CD44PNMTMAOBPRCP | |
| Hydrochloric Acid SCHEMBL4520528 | 0.79 | CD44 (0.96) | CD44PNMTMAOBPARP1PRCP | |
| Hydrochloric Acid SCHEMBL4506036 | 0.79 | CD44 (0.96) | CD44PNMTMAOBPARP1PRCP | |
| SCHEMBL11327051 | 0.78 | CD44 (0.62) | CD44PNMTMAOBPARP1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115636815-B | Preparation method and application of pomalidomide connected urea compound | 新乡学院 | 2023-10-27 | — | — | CN | claimed |
| CN-115636815-A | Preparation method and application of novel pomalidomide-linked urea compound | 新乡学院 | 2023-01-24 | — | — | CN | claimed |
| CN-115626916-A | Pomalidomide derivative and preparation method and application thereof | 河南科技大学第一附属医院 | 2023-01-20 | — | — | CN | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-12263156-B2 | Use of small molecule inhibitors of the BfrB:Bfd interaction in biofilms | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2023246944-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 中国科学院上海药物研究所 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023246944-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 中国科学院上海药物研究所 | 2023-12-28 | — | — | WO | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| CN-115697993-A | Pyrimidines as AXL inhibitors | 南京正大天晴制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115636815-A | Preparation method and application of novel pomalidomide-linked urea compound | 新乡学院 | 2023-01-24 | — | — | CN | disclosed |
| CN-115626916-A | Pomalidomide derivative and preparation method and application thereof | 河南科技大学第一附属医院 | 2023-01-20 | — | — | CN | disclosed |
| WO-2022199589-A1 | PYRIMIDINE DERIVATIVES | 南京明德新药研发有限公司 | 2022-09-29 | — | — | WO | disclosed |
| EP-1592684-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20040220222-A1 | Malonamide derivatives | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-11-04 | — | — | US | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| EP-0686625-A1 | ANTHRANILIC ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1995-12-13 | — | — | EP | disclosed |
| US-5026856-A | Bactericides | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1991-06-25 | — | — | US | disclosed |
| EP-0343560-A2 | Isoindoline derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12263156-B2 | Use of small molecule inhibitors of the BfrB:Bfd interaction in biofilms | BLVRB, Q6ZSR9, BTD | CD44 2953/4885PNMT 2669/4885ALDH1A1 2628/4885 |
| US-20040220222-A1 | Malonamide derivatives | BACE1, BACE2, APP | CD44 4872/4885PNMT 965/4885ALDH1A1 887/4885 |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | MSH2, PMS2, MSH6 | CD44 3212/4885PNMT 1030/4885ALDH1A1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.